Taxanes in the treatment of breast and ovarian cancers: current indications and results
Espié, M.; Cuvier, C.; Gorins, A.; Marty, M.
Contraception Fertilite Sexualite 26(11): 805-811
1998
ISSN/ISBN: 1165-1083 PMID: 9864888 Document Number: 487892
Since the last years, taxanes are among the most active molecules in the treatment of advanced breast and ovarian cancers. Concerning the ovarian cancer, Paclitaxel in association with Cisplatinum is about to become the first line reference protocol. Studies are going on in order to define the association and the optimal way of administration. Concerning breast cancer, Docetaxel seems to provide the most interesting response rates after failures of anthracyclines. In France, randomised studies in adjuvant situation have started with this molecule.